A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)

Trial Profile

A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs RGX 314 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors REGENXBIO
  • Most Recent Events

    • 20 Sep 2017 According to a REGENXBIO media release, the company plans to share an interim trial update by the end of 2017.
    • 20 Sep 2017 According to a REGENXBIO media release, the first cohort of six patients has been dosed in the trial. All six study sites are active to support enrollment in the next dose cohort that is projected to start after review by the Data Safety Monitoring Board this month.
    • 23 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top